These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25733584)

  • 21. Early Initiation of Sub-Anesthetic Ketamine Infusion in Adults with Vaso-Occlusive Crises Is Associated with Greater Reduction in Sickle Cell Pain Intensity: A Single Center's Experience.
    Kenney MO; Becerra B; Mallikarjunan A; Shah N; Smith WR
    Pain Med; 2022 Dec; 23(12):2042-2049. PubMed ID: 35708641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
    Torres L; Conran N
    Expert Opin Pharmacother; 2019 Feb; 20(2):173-186. PubMed ID: 30499731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.
    Weiner DL; Hibberd PL; Betit P; Cooper AB; Botelho CA; Brugnara C
    JAMA; 2003 Mar; 289(9):1136-42. PubMed ID: 12622584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized Trial of Yoga for Children Hospitalized With Sickle Cell Vaso-Occlusive Crisis.
    Moody K; Abrahams B; Baker R; Santizo R; Manwani D; Carullo V; Eugenio D; Carroll A
    J Pain Symptom Manage; 2017 Jun; 53(6):1026-1034. PubMed ID: 28192225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.
    Puri L; Nottage KA; Hankins JS; Anghelescu DL
    Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
    [No Abstract]   [Full Text] [Related]  

  • 28. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.
    Chang J; Patton JT; Sarkar A; Ernst B; Magnani JL; Frenette PS
    Blood; 2010 Sep; 116(10):1779-86. PubMed ID: 20508165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease.
    Ender KL; Krajewski JA; Babineau J; Tresgallo M; Schechter W; Saroyan JM; Kharbanda A
    Pediatr Blood Cancer; 2014 Apr; 61(4):693-6. PubMed ID: 24249617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
    De Franceschi L; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G
    Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.
    Brousseau DC; Scott JP; Badaki-Makun O; Darbari DS; Chumpitazi CE; Airewele GE; Ellison AM; Smith-Whitley K; Mahajan P; Sarnaik SA; Casper TC; Cook LJ; Dean JM; Leonard J; Hulbert ML; Powell EC; Liem RI; Hickey R; Krishnamurti L; Hillery CA; Nimmer M; Panepinto JA;
    Blood; 2015 Oct; 126(14):1651-7. PubMed ID: 26232172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease.
    Goldman RD; Mounstephen W; Kirby-Allen M; Friedman JN
    Pediatrics; 2013 Dec; 132(6):e1634-41. PubMed ID: 24276838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial.
    Orringer EP; Casella JF; Ataga KI; Koshy M; Adams-Graves P; Luchtman-Jones L; Wun T; Watanabe M; Shafer F; Kutlar A; Abboud M; Steinberg M; Adler B; Swerdlow P; Terregino C; Saccente S; Files B; Ballas S; Brown R; Wojtowicz-Praga S; Grindel JM
    JAMA; 2001 Nov; 286(17):2099-106. PubMed ID: 11694150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
    Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
    Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).
    Elshazly SA; Heiba NM; Abdelmageed WM
    Hematology; 2014 Jan; 19(1):52-9. PubMed ID: 23735470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New and emerging treatments for vaso-occlusive pain in sickle cell disease.
    Dampier C
    Expert Rev Hematol; 2019 Oct; 12(10):857-872. PubMed ID: 31364883
    [No Abstract]   [Full Text] [Related]  

  • 38. Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease.
    Gu JM; Yuan S; Sim D; Abe K; Liu P; Rosenbruch M; Bringmann P; Kauser K
    Exp Hematol; 2018 Apr; 60():73-82.e3. PubMed ID: 29337222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study.
    Nottage KA; Hankins JS; Faughnan LG; James DM; Richardson J; Christensen R; Kang G; Smeltzer M; Cancio MI; Wang WC; Anghelescu DL
    Clin Trials; 2016 Aug; 13(4):409-16. PubMed ID: 27000103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis.
    Manwani D; Xu C; Lee SK; Amatuni G; Cohen HW; Carullo V; Morrone K; Davila J; Shi PA; Ireland K; Keenan J; Frenette PS
    Complement Ther Med; 2020 Aug; 52():102481. PubMed ID: 32951731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.